VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies

Inclusion Criteria:

Disease criteria:

Patients with the following hematological malignancies:

Acute Myeloid Leukemia (AML) in complete remission (CR)
Acute Lymphoblastic Leukemia (ALL) in complete remission (CR)
Myelodysplastic Syndrome (MDS) requiring intensive chemotherapy
Non-Hodgkin lymphoma in complete or partial remission
Hodgkin lymphoma in complete or partial remission

Age Criteria:

- 18 years up to 65 years.

Organ Function and Performance Status Criteria:

- Performance status score: Karnofsky Score ≥60

Adequate major organ function defined as:

Left ventricular ejection fraction ≥40%
Pulmonary function test demonstrating DLCO ≥50% predicted and corrected for hemoglobin
Serum creatinine ≤ 2 mg/dL
Transaminases ≤ 3x ULN
Bilirubin ≤3x ULN except for in case of Gilbert's syndrome or ongoing hemolysis
Ability to understand and the willingness to sign a written informed consent document

Donor availability:

-Lack of suitable HLA matched related or unrelated donor available within 30 days or less if BMT is urgent in the opinion of the transplant physician.

Exclusion Criteria:

Progressive, persistent disease or active malignancy
Greater than 10% blasts on bone marrow biopsy in patients with MDS
Chemotherapy naïve
History of myelofibrosis
Presence of Bone Marrow Fibrosis grade 2/3
Presence of donor specific anti-HLA antibodies against available UCB units at A, B, C or DR loci, with a mean fluorescence intensity (MFI)>1000
History of prior allogeneic stem cell transplantation
Uncontrolled viral, bacterial or fungal infection
History of HIV infection
Presence of active CNS disease at the time of transplantation
Pregnant or breastfeeding female
Inability or unwillingness to use effective birth control.